Claims for Patent: 8,066,984

Summary for Patent: 8,066,984

Title:	Modified vaccinia virus strains for use in diagnostic and therapeutic methods
Abstract:	Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including cancer, and as anti-tumor and/or antiangiogenic agents. The viruses also can be used in diagnostic methods.
Inventor(s):	Szalay; Aladar A. (Highland, CA), Frentzen; Alexa (San Diego, CA), Yu; Yong A. (San Diego, CA), Chen; Nanhai (San Diego, CA), Zhang; Qian (San Diego, CA)
Assignee:	Genelux Corporation (San Diego, CA)
Application Number:	12/080,766
Patent Claims:	1. A method of treatment of cancer, comprising administering a LIVP virus to a subject for the treatment of a tumor or metastasis, wherein the LIVP virus contains heterologous nucleic acid encoding an anti-vascular endothelial growth factor (VEGF) antibody or an antibody fragment thereof, wherein: the LIVP virus comprises an inactivated the hemagglutinin (HA) gene locus, thymidine kinase (TK) gene locus or F14.5L gene; and the anti-VEGF antibody or fragment thereof is inserted into a non-essential locus in the virus operatively linked to a promoter for expression. 2. The method of claim 1, wherein the antibody is an anti-vascular endothelial growth factor (VEGF) single chain antibody. 3. The method of claim 1, wherein the anti-VEGF antibody is a single chain form of Bevacizumab. 4. The method of claim 2, wherein the anti-VEGF single chain antibody comprises is antibody G6. 5. The method of claim 1, wherein the heterologous nucleic acid encodes a fusion protein of the anti-VEGF antibody and a detectable polypeptide. 6. The method of claim 2, wherein the anti-VEGF single chain antibody is encoded as a FLAG fusion protein. 7. The method of claim 2, wherein the anti-VEGF single chain antibody is the single chain antibody designated G6-FLAG. 8. The method of claim 1, wherein the virus comprises a modified hemagglutinin (HA) gene, thymidine kinase (TK) gene and F14.5L gene, wherein: one or more of the modifications comprises insertion of a heterologous non-coding nucleic acid molecule into the HA gene locus, TK gene locus and/or F14.5L gene locus; non-coding nucleic acid does not encode a polypeptide; and a functional HA, TK, and F14.5L polypeptide is not expressed. 9. The method of claim 1, wherein the virus is GLV-1h68 comprising the heterologous nucleic acid encoding the anti-VEGF antibody or an antibody fragment thereof. 10. The method of claim 1, wherein the heterologous nucleic acid is inserted into the TK gene locus of the virus. 11. The method of claim 1, wherein the virus is GLV-1h107, GLV-1h108 or GLV-1h109. 12. The method of claim 1, wherein the virus contains a nucleic acid molecule that encodes a detectable protein or a protein that induces a detectable signal. 13. The method of claim 12, wherein the detectable protein or protein that induces a detectable signal is selected from among a luciferase, a fluorescent protein, an iron storage molecule, an iron transporter, an iron receptor and a protein that binds a contrasting agent, chromophore or a compound or detectable ligand. 14. The method of claim 1, wherein the virus is administered in a pharmaceutical composition comprising the virus and a pharmaceutically acceptable carrier. 15. The method of claim 14, wherein the compositions is formulated for local or systemic administration. 16. The method of claim 1, further comprising administering another anti-cancer agent or treatment. 17. The method of claim 16, wherein the anticancer agent or treatment is selected from among a cytokine, a chemokine, a growth factor, a photosensitizing agent, a toxin, an anti-cancer antibiotic, a chemotherapeutic compound, a radionuclide, an angiogenesis inhibitor, a signaling modulator, an anti-metabolite, an anti-cancer vaccine, an anti-cancer oligopeptide, a mitosis inhibitor protein, an antimitotic oligopeptide, an anti-cancer antibody, an immunotherapeutic agent, hyperthermia therapy, a bacterium, radiation therapy and a combination of any of the preceding thereof. 18. The method of claim 16, wherein the anticancer agent or treatment is administered simultaneously, sequentially or intermittently. 19. The method of claim 1, wherein the tumor is selected from among a bladder tumor, breast tumor, prostate tumor, carcinoma, basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, brain cancer, central nervous system (CNS) cancer, glioma tumor, cervical cancer, choriocarcinoma, colon and rectum cancer, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, cancer of the head and neck, gastric cancer, intra-epithelial neoplasm, kidney cancer, larynx cancer, leukemia, liver cancer, lung cancer, lymphoma, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, melanoma, myeloma, neuroblastoma, oral cavity cancer, ovarian cancer, pancreatic cancer, retinoblastoma, rhabdomyosarcoma, rectal cancer, renal cancer, cancer of the respiratory system, sarcoma, skin cancer, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, and cancer of the urinary system. 20. The method of claim 1, further comprising detecting the LIVP virus in the subject, whereby detection allows visualization or monitoring of a tumor in the subject. 21. The method of claim 20, wherein the virus expresses a detectable protein or a protein that induces a detectable signal. 22. The method of claim 21, wherein the detectable protein or protein that induces a detectable signal is selected from among a luciferase, a fluorescent protein, an iron storage molecule, an iron transporter, an iron receptor and a protein that binds to a contrasting agent, chromophore or a compound or detectable ligand that can be detected. 23. The method of claim 20, wherein the virus is detected by fluorescence imaging, magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), positron emission tomography (PET), scintigraphy, gamma camera, a .beta.+ detector, a .gamma. detector or a combination thereof. 24. The method of claim 1, wherein the virus comprises a modified hemagglutinin (HA) gene locus, thymidine kinase (TK) gene locus and F14.5L gene locus. 25. The method of claim 24, wherein each of the hemagglutinin (HA) gene locus, thymidine kinase (TK) gene locus and F14.5L gene locus comprises heterologous nucleic acid, whereby the HA gene, TK gene and F14.5L gene are inactivated. 26. The method of claim 16, wherein the treatment is radiation therapy. 27. The method of claim 26, wherein radiation therapy is selected from among treatment with radionuclides, radioimmunotherapy and proton beam treatment. 28. The method of claim 11, further comprising administering another anti-cancer treatment, wherein the treatment is administered before, after, sequentially, simultaneously or intermittently with treatment with the virus. 29. The method of claim 28, wherein the other treatment is radiation therapy or chemotherapy.

Details for Patent 8,066,984

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2021-07-31